

## REFERENCES

1. Kanel WB and McGee DL. Diabetes and cardiovascular disease: the Framingham study. *JAMA*. 1979;241:2035-8.
2. Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. *Eur J Pharmacol*. 1986;132(1):75-8.
3. Kamata K, Kobayashi T. Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes. *Br J Pharmacol*. 1996;119(3):583-9.
4. Kobayashi T, Kamata K. Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes. *Br J Pharmacol*. 1999;127(4):835-42.
5. De Vriese AS, Stoenoiu MS, Elger M, Devuyst O, Vanholder R, Kriz W, Lameire NH. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. *Kidney Int*. 2001;60:202-10.
6. Kiff RJ, Gardiner SM, Compton AM, Bennet T. Impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus. *Br J Pharmacol*. 1991;103:1357-62.
7. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. *Am J Physiol Heart Circ Physiol*. 2003;285:H2392-98.
8. Endemann D, Pu Q, De Ciuceis C, Savoia C, Viridis A, Neves MF, Touyz RM, Schiffrin EL. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. *Hypertension*. 2004;43:399-404.
9. Bannister L. Haemolymphoid system - Endothelium. In, *Gray's Anatomy*, Peter LW. editors. 38th ed. Churchill Livingstone. 1995;1456-8.
10. Cannon RO. III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. *Clin Chem*. 1998;44:1809-19.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980;288:373-6.
12. Rang HP, Dale MM, Ritter JM, editor. *Pharmacology*. 4th ed. London: Churchill Livingstone. 1999;281-4.
13. Ramesh KV, Ashok Shenoy K. Endothelial dysfunction: many ways to correct - trends that promise. *Indian Journal of Pharmacology*. 2003;35:73-82.

14. Iyengar R, Stuehr DJ, Marletta MA. Macrophage synthesis of nitrite, nitrate and N-nitrosoamines: precursors and role of the respiratory burst. *Proc Natl Acad Sci USA*. 1987;84:6369-73.
15. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature*. 1987;327:524-6.
16. Kamiya A, Ando J, Shibata M, Masuda H. Role of fluid shear stress in physiological regulation of vascular structure and function. *Biorheology*. 1988;25:272-8.
17. Miller MJ. Preconditioning for cardioprotection against ischemia reperfusion injury: The roles of nitric oxide, reactive oxygen species, heat shock proteins, reactive hyperemia and antioxidants- a mini review. *Can J Cardiol*. 2001;17:1075-82.
18. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res*. 2000;87:840-4.
19. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF: NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. *Hypertension*. 2002;40:755-62.
20. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. *Circulation*. 1998;97:2494-8.
21. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. *Hypertension*. 1999;33:1353-8.
22. van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, Palacios-Callender M, Erusalimsky JD, Quaschnig T, Malinski T, Gygi D, Ullrich V, Luscher TF. Enhanced peroxynitrite formation is associated with vascular aging. *J Exp Med*. 2000;192:1731-44.
23. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. *Circulation*. 1998;97:363-8.
24. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation*. 1998;97:2222-9.
25. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation*. 2001;104:2673-8.

26. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. *Hypertension*. 2001;38:606-11.
27. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. *J Am Soc Nephrol*. 2001;12:2747-52.
28. Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ. Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. *Kidney Int*. 2003;63:1433-42.
29. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. *Kidney Int*. 2002;61:586-90.
30. Frisbee JC, Stepp DW. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. *Am J Physiol Heart Circ Physiol*. 2001;281:H1304-11.
31. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, Kim CD. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. *Diabetes*. 2002;51:522-7.
32. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and *in vivo* monitoring of ROS. *Circulation*. 2003;108:1912-6.
33. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature. *Hypertension*. 2003;42:1075-81.
34. Touyz RM, Schiffrin EL. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. *Hypertension*. 1999;34:976-82.
35. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: Role of xanthineoxidase and extracellular superoxide dismutase. *Circulation*. 2002;106:3073-8.
36. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly-(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. *J Clin Invest*. 2003;112:1049-57.
37. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. *Proc Natl Acad Sci USA*. 1998;95(16):9220-5.

38. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griending KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest.* 1996;97:1916-23.
39. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPAR[alpha] activator effects on Ang II-induced vascular oxidative stress and inflammation. *Hypertension.* 2002;40:866-71.
40. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: Benefits of AT1 receptor blockade. *J Am Coll Cardiol.* 2003;42:911-3.
41. Schiffrin EL. Beyond blood pressure: the endothelium and atherosclerosis progression. *Am J Hypertens.* 2002;15:115S-22S.
42. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. *J Am Coll Cardiol.* 2003;41:1769-75.
43. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroberardino P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. *Circulation.* 2001;104:191-6.
44. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation.* 2001;104:1336-42.
45. Segarra A, Chacon P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolome J, Camps J, Moliner E, Pelegri A, Marco F, Olmos A, Piera L. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. *J Am Soc Nephrol.* 2001;12:1255-63.
46. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. *Diabetes.* 2002;51:1157-65.
47. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. *Circulation.* 2002;106:820-5.
48. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. *Lancet.* 1998;351:88-92.

49. Kobayashi N, Mori Y, Mita S, Nakano S, Kobayashi T, Tsubokou Y, *et al.* Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats. *Eur J Pharmacol.* 2001;422:149-57.
50. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. *N Engl J Med.* 1995;332(8):481-7.
51. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation.* 1997;95(5):1126-31.
52. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, Schmieder RE. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. *J Am Coll Cardiol.* 2001;37:1351-8.
53. Alberts AW. Discovery, biochemistry and biology of lovastatin. *Am. J. Cardiol.* 1988;62:10J-15J.
54. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. *Circulation.* 1995;92(6):1582-9.
55. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? *Circulation.* 2004;109(21 Supl 1):II18-26. Review.
56. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefter DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. *Nat Med.* 2000;6(9):1004-10.
57. Laufs U, La Fata V, Plutzky J, *et al.* Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation.* 1998;97:1129-35.
58. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. *Circ Res.* 1998;83: 683-90.
59. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. *J Clin Invest.* 1998;101:2711-9.
60. Liao JK. Endothelium and acute coronary syndromes. *Clin Chem.* 1998;44(8 Pt 2):1799-808.

61. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). *Arterioscler Thromb Vasc Biol.* 2002;22(7):1162-7.
62. Hussein O, Schlezinger S, Rosenblat M, Keider S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. *Atherosclerosis.* 1997;128:11-8.
63. Suzumura K, Yasuhara M, Tanaka K, Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein *in vitro*. *Biochem Pharmacol.* 1999;57:697-703.
64. Yasuhara M, Suzumura K, Tanaka K. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. *Biol Pharm Bull.* 2000;23:570-4.
65. Rikitake Y, Kawashima S, Takeshita S. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. *Atherosclerosis.* 2001;154:87-96.
66. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. *Atherosclerosis.* 1998;138:271-80.
67. Pietsch A, Erl Wand Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. *Biochem Pharmacol.* 1996;52:433-9.
68. Umetani N, Kanayama Y, Okamura M, Negoro N, Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor on THP-I human macrophages. *Biochim Biophys Acta.* 1996;1303:199-206.
69. Draude G, Hrboticky N, Lorenz RL. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. *Biochem Pharmacol.* 1999;57:383-6.
70. Wassmann S, Laufs U, Muller K. Cellular antioxidant effects of atorvastatin *in vitro* and *in vivo*. *Arterioscler Thromb Vasc Biol.* 2002; 2:300-5.
71. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. *Circulation.* 2002;105(14):1656-62.

72. Blaha V, Zadak Z, Solichova D, Bratova M, Havel E. Hypcholesterolemic effect of pravastatin is associated with increased content of antioxidant vitamin-E in cholesterol fractions. *Acta Medica*. 1998;41:87-90.
73. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. *Am J Cardiol*. 1996;77:851-4.
74. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. *Circ Res*. 2002;91:173-9.
75. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. *N Engl J Med*. 1995;332(8):488-93.
76. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. *J Am Coll Cardiol*. 2000;35(1):1-10.
77. Diomedede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M. *In vivo* anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. *Arterioscler Thromb Vasc Biol*. 2001;21(8):1327-32.
78. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM 3rd, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. *Circulation*. 2001;103(21):2598-603.
79. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. *Int J Cardiol*. 2001;77(2-3):247-53.
80. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. *Int J Immunopharmacol*. 1996;18(11):669-75.
81. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. *Nat Med*. 2001;7(6):687-92.
82. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. *Arterioscler Thromb Vasc Biol*. 1999;19(12):2894-900.
83. Libby P. Molecular bases of the acute coronary syndromes. *Circulation*. 1995;91(11):2844-50.

84. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. *Proc Natl Acad Sci U S A*. 1991;88(18):8154-8.
85. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. *Cardiovasc Res*. 2000;47(4):648-57.
86. Crisby M, Nordin-Fredriksson G, Shah PK. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. *Circulation*. 2001;103:926-33.
87. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. *N Engl J Med*. 1986;315(16):983-9.
88. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. *Circulation*. 1995;92(11):3172-7.
89. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. *Arterioscler Thromb Vasc Biol*. 1995;15(2):247-51.
90. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J, Habib A. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. *J Biol Chem*. 2001;276(50):46849-55.
91. Alfon J, Royo T, Garcia-Moll X, Badimon L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. *Arterioscler Thromb Vasc Biol*. 1999;19(7):1812-7.
92. Bourcier T, Libby P. MG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. *Arterioscler Thromb Vasc Biol*. 2000;20(2):556-62.
93. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. *Arterioscler Thromb Vasc Biol*. 1997;17(2):265-72.
94. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Kashitan CE. Lovastatin inhibits lipopolysaccharide-induced NF- B activation in human mesangial cells. *Nephrol Dial Transplant*. 1996;11:990-6.



95. Kaneider NC, Reinisch CM, Dunzendorfer S. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. *Atherosclerosis*. 2001;158:23-33.
96. Knapp AC, Huang J, Starling G. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fasligand and cytokine-induced cell death. *Atherosclerosis*. 2000;152:217-27.
97. Chen Z, Fukutomi T, Zago AC. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. *Circulation*. 2002;106:20-3.
98. Tschöpe C, Reinecke A, Seidl U, Yu M, Gavrilluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats. *Am J Physiol*. 1999;277:2333-40.
99. Angulo J, Rodriguez-Manas L, Peiro C, Neira M, Marin J, Sanchez-Ferrer CF. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. *Naunyn-Schmiedeberg's Arch Pharmacol*. 1998;358:529-37.
100. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Münzel T. Increased NADH-oxidase-mediated superoxide production in the early stage of atherosclerosis: evidence for involvement of the renin-angiotensin system. *Circulation*. 1999;99:2027-33.
101. Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, Kuhl U. Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. *Med Sci Monit*. 2002;8(5):MT59-71.
102. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-9.
103. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003;361:1149-58.
104. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. *Arterioscler Thromb Vasc Biol*. 2000;20:61-9.

105. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. *J Cardiovasc Pharmacol Ther.* 2001;15:211-8.
106. Maron DJ, Fazio S, Linton MF. Current perspectives of statins. *Circulation.* 2000;101:207-23.
107. Takemoto M, Liao J. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arterioscl Thromb Vasc Biol.* 2001;21:1712-9.
108. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. *Circulation.* 2001;104:376-9.
109. Medgett IE. Effect of neuronal uptake blockade on the amplifying effect of serotonin on sympathetic vasoconstriction in rat autoperfused hindlimb. *J Cardiovasc Pharmacol.* 1987;10 [Suppl 3]:S65-8.
110. Brouwers-Ceiler DL, Nelissen-Vrancken HJMG, Smits JFM. Effect of nitric oxide synthase inhibition on the acetylcholine response in the perfused hind limb of rats. *Eur J Pharmacol.* 1996; 307:65-8.
111. Dai FX, Diederich A, Skopec J, Diederich D. Diabetic-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. *J Am Soc Nephrol.* 1994;41:1327-36.
112. Mercurio G, Zoncu S, Saiu F, Sarais C, Rosano GM. Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. *Am J Cardiol.* 2002; 90:747-50.
113. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. *Cardiovasc Res.* 2001;52:299-305.
114. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. *Arteriosclerol Thromb Vasc Biol.* 2002;22:799-804.
115. Sheu WH, Chen YT, Lee WJ. Improvement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients. *Diabetes Care.* 2001;24:1499-501.
116. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2002;87:563-8.

117. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. *J Am Coll Cardiol.* 2000; 36:410-6.
118. Cosentino F, Hishikawa K, Katusic ZS, *et al.* High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. *Circulation.* 1997;96:25-8.
119. King GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. *Ann Med.* 1996;28:427-32.
120. Dusting GJ, Fennessy P, Yin ZL, Gurevich V. Nitric oxide in atherosclerosis: vascular protector or villain? *Clin Exp Pharmacol Physiol Suppl.* 1998;25:S34-41.
121. Chowienczyk PJ, Brett SE, Gopaul NK, Meeking D, Marchetti M, Russell-Jones DL, Anggard EE, Ritter JM. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes. *Diabetologia.* 2000;43:974-7.
122. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. *Cardiovasc Res.* 2000;47:457-64.
123. El-seweidy MM, El-Swefy SE, Ameen RS, Hashem RM. Effect of age receptor blocker and/or anti-inflammatory coadministration in relation to glycation, oxidative stress and cytokine production in stz diabetic rats. *Pharmacol Res.* 2002;45(5):391-8.
124. Felaco M, Grilli A, De Lutiis MA, Patruno A, Libertini N, Taccardi AA, Di Napoli P, Di Giulio C, Barbacane R, Conti P. Endothelial nitric oxide synthase (eNOS) expression and localization in healthy and diabetic rat hearts. *Ann Clin Lab Sci.* 2001;31(2):179-86.
125. Perreault M, Dombrowski L, Marette A. Mechanism of impaired nitric oxide synthase activity in skeletal muscle of streptozotocin-induced diabetic rats. *Diabetologia.* 2000;43(4):427-37.
126. Hoshiyama M, Li B, Yao J, Harada T, Morioka T, Oite T. Effect of high glucose on nitric oxide production and endothelial nitric oxide synthase protein expression in human glomerular endothelial cells. *Nephron Exp Nephrol.* 2003;95(2):e62-8.
127. Chen L, Haught WH, Yang B. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. *J Am Coll Cardiol.* 1997;30:569-75.
128. Girona J, La Ville AE, Sola R. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. *Am J Cardiol.* 1999;83:846-51.

129. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. *J Cardiovasc Pharmacol.* 2002;40(4):611-7.
130. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. *Circulation.* 2001;104(15):1767-72.
131. Hattori Y, Nakanishi N, Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. *Cardiovasc Res.* 2002;54(3):649-58.
132. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. *Am J Cardiol.* 2002;89:1117-9.
133. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med.* 1999;340(2):115-26.
134. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A.* 1991;88:4651-5.
135. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. *J Exp Med.* 2000;191(1):189-94.
136. Petzelbauer P, Pober JS, Keh A, Braverman IM. Inducibility and expression of microvascular endothelial adhesion molecules in lesional, perilesional, and uninvolved skin of psoriatic patients. *J Invest Dermatol.* 1994;103:300-5.
137. Groves RW, Ross EL, Barker JN, MacDonald DM. Vascular cell adhesion molecule-1 (VCAM-1). Expression in normal and diseased skin and regulation *in vivo* by interferon gamma. *J Am Acad Dermatol.* 1993;29:67-72.
138. Huang KC, Chen CW, Chen JC, Lin WW. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. *J Biomed Sci.* 2003;10:396-405.
139. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. *J Clin Invest.* 1998;101:1905-15.

140. Booth G, Scalia R, Lefer AM. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. *Am J Physiol Endocrinol Metab.* 2001;280(6):E848-56.
141. Empen K, Frost RJ, Geiss HC, Otto C, Parhofer KG. Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial. *Cardiovasc Diabetol.* 2003;2:17-22.
142. Nawawi H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. *Horm Metab Res.* 2003;35:479-85.
143. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. *Atherosclerosis.* 2002;162:179-85.
144. Johnson G L and Lapadat R. Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases. *Science.* 2002;298:1911-2.
145. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr. Rev.* 2001;2:153-83.
146. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. *Nat Rev Drug Discov.* 2003;2(9):717-26.
147. Kyriakis J M and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. *Physiol Rev.* 2001;1:807-69.
148. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. *J Cell Physiol.* 2002;192(1):1-15.
149. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. *Curr Opin Cell Biol.* 1999;11:211-8.
150. Baldwin AS Jr.. The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annu Rev Immunol.* 1996;14:649-83.
151. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, and Miyamoto S. Rel/NF- $\kappa$ B family: intimate tales of association and dissociation. *Genes Dev.* 1996;9:2723-35.
152. Collins T. Endothelial nuclear factor- $\kappa$ B and the initiation of the atherosclerotic lesion. *Lab Invest.* 1993;68:499-508.

153. Hoyos B, Ballard DW, Bohnlein E, Siekevitz M, Greene WC. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. *Science*. 1989;244(4903):457-60.
154. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. *Mol Cell Biol*. 1990;10(5):2327-34.
155. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. *J Exp Med*. 1990;171(1):35-47.
156. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. *J Biol Chem*. 1994;269(7):4705-8.
157. Sun Y and Oberley LW. Redox regulation of transcriptional activators. *Free Radic. Biol. Med*. 1996;21: 335-48.
158. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, and Okumura K. Differential regulation of Ikappa B kinase and by two upstream kinases, NF-kappaB inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. *Proc. Natl. Acad. Sci*. 1998;95:3537-42.
159. Wang X, Martindale JL, Liu Y, Holbrook NJ. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. *Biochem J*. 1998;333 ( Pt 2):291-300.
160. Granet C, Boutahar N, Vico L, Alexandre C, Lafage-Proust MH. MAPK and SRC-kinases control EGR-1 and NF-kappa B inductions by changes in mechanical environment in osteoblasts. *Biochem Biophys Res Commun*. 2001;284(3):622-31.
161. Park J H and Levitt L. Overexpression of Mitogen-activated protein kinase (ERK1) enhances T-cell cytokine gene expression: role of AP1, NF-AT, and NF-B. *Blood*. 1993;82:2470-7.
162. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase *in vitro* and *in vivo*. *J Biol Chem*. 1995;270(46):27489-94.
163. Cohen MP, Shea E, Chen S, Shearman CW. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. *J Lab Clin Med*. 2003;141(4):242-9.
164. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. *Biochem Biophys Res Commun*. 2004;314(1):197-207.

165. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J. Atorvastatin reduces NF- B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. *Atherosclerosis*. 1999;147:253-61.
166. Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Hernández-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Díaz C, Hernández G, Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. *Atherosclerosis*. 2002;160:49-58.
167. Janssen-Heininger YM, Macara I, Mossman BT. Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. *Am J Respir Cell Mol Biol*. 1999;20(5):942-52.
168. Yamamoto A, Hoshi K, Ichihara K, Fluvastatin. An inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenging free radicals and inhibits lipid peroxidation in rat microsomes. *Eur J Pharmacol*. 1998;361:143-9.
169. Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. *J Immunol*. 2000;165(5):2712-8.
170. Mehta JL, Li DY, Chen HJ. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. *Biochem Biophys Res Commun*. 2001;289:857-61.
171. Bassa BV, Roh DD, Vaziri ND. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. *Biochim Biophys Acta*. 1999;1449:137-49.
172. Park JK, Muller DN, Mervaala EM. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. *Kidney Int*. 2000;58:1420-30.
173. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, Ro HK, Shong M. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. *Exp Mol Med*. 2002;34(6):451-61.